News

Results of Operations Year ended December 31, 2008 compared to year ended December 31, 2007 Cost of Revenues and Gross Profit Cost of revenue for 2008, was $2,879,839

DKSH will provide Cardima with an integrated solution, including regulatory, logistics, marketing, sales, physician training, distribution and after-sales services. Cardima’s electrophysiology products and surgical ablation system have received

Under the terms of the agreement Alnara will obtain exclusive worldwide rights to develop and market liprotamase. Robert Beall, president and CEO of the Cystic Fibrosis Foundation Therapeutics

The agreement resolves litigation that was pending in the US District Court of Texas with respect to certain CR Bard products. The technology generally relates to surgical devices

The company expects to begin Phase III clinical trials at multiple sites across the US in the second quarter of 2009. As part of this investigational new drug

Deni Zodda, the company’s chief business officer, has been appointed interim CFO and corporate secretary. The company has also hired Joseph Warusz as a consultant, who will serve

Boehringer Ingelheim has reported that the last patient has completed treatment in the Phase III randomized evaluation of long term anticoagulant therapy study. This randomized evaluation of long

According to NeuroVasx, the cPAX system is a minimally invasive device for the embolization of cerebral aneurysms, abnormal bulges or sacs in the wall of an artery in

Delcath Systems, a medical technology company, has reported that the data and safety monitoring board has unanimously recommended continuation of the company’s Phase III clinical trial for inoperable